BOD Australia Ltd - First medicinal cannabis prescriptions received in the UK
BOD Australia Ltd (ASX:BDA)

First medicinal cannabis prescriptions received in the UK

Published May 04, 2020

What happened?


What's happened?

Bod Australia Ltd (ASX: BDA, “Bod”) has received its first prescriptions for MediCabilis™ from patients in the United Kingdom.

What are the key highlights?

  1. The prescriptions were received from a leading medicinal cannabis organisation, which has a number of clinics in London and the UK more broadly.
  2. The United Kingdom is a major market opportunity for Bod with approximately 7.3m consumers using CBD annually. It is expected to grow in value to US$3Bn per annum by 2024 and to €8.8Bn by 2028. This would represent a market four times larger than Australia in 2028.
  3. With a presence in Australia and now the United Kingdom, Bod expects prescription volumes to increase materially in the coming months, particularly as brand awareness for MediCabilis™ grows amongst physicians and patients in the UK.

CEO's summary

Jo Patterson CEO of BOD Australia Ltd has provided a statement.
Jo Patterson
Jo Patterson
CEO, BOD Australia Ltd

"Securing the first international prescriptions for MediCabilis™ has been months in the making and it is the critical catalyst for a rapid increase in prescription volumes in the United Kingdom. Our UK market entry has included rigorous patient and physician education initiatives, as well as collaborative work with our distribution partners to ensure we have the necessary infrastructure in place to scale operations rapidly. This is not quickly or easily replicated, so we have an immediate market advantage here. Bod is now actively engaging with physicians and medical organisations across the UK in a bid to further educate them about the MediCabilis™ range. We are encouraged by the response we are receiving and growing patient demand underpins our confidence that this will be a major growth market for MediCabilis™. The UK is spearheading Bod’s international expansion efforts and will act as the springboard into Europe. We have a large number of growth initiatives underway, including new market entries and product introductions. We look forward to communicating our successes.”

Analysts thoughts

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
SmallCapInsider
Written by SmallCapInsider
Published May 04, 2020

Bod Australia ("Bod") continues to execute by building on its channels to market both domestically and internationally. Bod also continues to state that prescription growth will increase substantially in the near term. This is following up from already strong previous historical quarter-on-quarter growth from Q2 to Q3 of FY2020 of 135% (from A$0.536m to $1.257m).

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Bod continues to achieve strong revenue growth in FY2020
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) advises that it has achieved strong revenue growth in recent months...
5 years ago
Bod continues to achieve upward trajectory in medicinal cannabis prescriptions
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has advised that it is continuing to experience significant uptake...
5 years ago
First medical cannabis prescriptions received from UK patients participating in Project Twenty21
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has confirmed first prescriptions of the Company’s MediCabilis™ med...
5 years ago
Around the web
Powered by  
  • Company
    BOD Australia Ltd
  • Website
  • Sector
    Distributors
  • Industry
    Distributors
  • Code
    ASX:BDA
  • Socials
View BOD Australia Ltd's Profile

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up